Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
复制标题
DOI：
10.1016/j.pnpbp.2008.08.020
复制
发表时间：
2008-12-12
影响因子：
5.6
通讯作者：
Rezazadeh, Shams-Ali
中科院分区：
文献类型：
--
作者：
Akhondzadeh, Shahin;Malek-Hosseini, Mojgan;Rezazadeh, Shams-Ali
据报道，在以阴性症状为主的住院患者中，当将5 HT 2A/2C拮抗剂利坦色林添加到抗精神病药中时，可改善阴性症状。然而，迄今为止，已发表的研究结果相互矛盾。本研究采用随机双盲对照研究方法，探讨利培酮与利坦色林联合应用对慢性精神分裂症伴显著阴性症状患者的强化治疗效果。本研究的合格参与者为40例慢性精神分裂症患者。所有患者均为住院患者，处于疾病的活动期，符合DSM-IV-TR精神分裂症标准。患者以随机方式分配，20例接受利培酮6 mg/天+利坦色林12 mg/天（6 mg bid），20例接受利培酮6 mg/天+安慰剂。结果的主要措施是阳性和阴性症状量表（PANSS）。尽管两种方案在试验期间均显著降低了阳性、阴性和一般精神病理学症状评分，但利培酮和利坦色林联合用药在降低阴性症状和PANSS总分方面优于单用利培酮。本研究表明，利坦色林作为精神分裂症阴性症状的一种潜在的连续治疗策略。然而，需要更大规模的对照试验的结果。然后才能推荐广泛的临床应用。(c)2008 Elsevier Inc保留所有权利。
It was reported that ritanserin, a 5HT2A/2C antagonist, improves negative symptoms when added to neuroleptics in inpatients with predominantly negative symptoms. Nevertheless, the results of published studies are contradictory so far. This study was designed to investigate the effect of ritanserin added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double blind and randomized clinical trial. Eligible participants in this study were 40 patients with chronic schizophrenia. All patients were inpatients and were in the active phase of the illness, and met DSM-IV-TR criteria for schizophrenia. Patients were allocated in a random fashion, 20 to risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid) and 20 to risperidone 6 mg/day plus placebo. The principal measure of the outcome was Positive and Negative Syndrome Scale (PANSS). Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of risperidone and ritanserin showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores. The present study indicates ritanserin as a potential adjunctive treatment strategy for the negative symptoms of schizophrenia. Nevertheless, results of larger controlled trials are needed. before recommendation for a broad clinical application can be made. (c) 2008 Elsevier Inc All rights reserved.